Nifedipine: Side Effects, Uses & Monitoring
I.
- Data source
- FDA labeling via NIH DailyMed (label 1c027c28…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Giddiness | 27% |
| Flushing, heat sensation | 25% |
| Headache | 15.8% |
| Weakness | 12% |
| Nausea, heartburn | 11% |
| Muscle cramps, tremor | 8% |
| Nasal congestion, sore throat | 8% |
| Peripheral edema | 7% |
| Nervousness, mood changes | 7% |
| Palpitations | 7% |
| Dyspnea, cough, wheezing | 6% |
| Fatigue | 5.9% |
| Dizziness | 4.5% |
| Constipation | 3.3% |
| Nausea | 3.3% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
I. Vasospastic Angina Nifedipine Extended-Release Tablets, USP are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-Release Tablets, USP may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-Release Tablets, USP are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in…
Conditions associated with Nifedipine in labeling
Chest Pain
Discomfort or pain in the chest that can range from minor muscle strain to a life-threatening heart condition....
Hypertension
Chronically elevated blood pressure that puts strain on the heart, blood vessels, kidneys, and brain. Often ha...
Hypotension
Abnormally low blood pressure that can cause dizziness, lightheadedness, and fainting....
Frequently Asked Questions
What is Nifedipine used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Nifedipine?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Nifedipine. Individual risk varies.
Does Nifedipine require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Nifedipine.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.